4.6 Article

Effects of a beverage rich in (poly)phenols on established and novel risk markers for vascular disease in medically uncomplicated overweight or obese subjects: A four week randomized placebo-controlled trial

Journal

ATHEROSCLEROSIS
Volume 246, Issue -, Pages 169-176

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2016.01.004

Keywords

Cardiovascular risk; Overweight; Obesity; Flavonoids; HydroxyCinnamates; Vascular function; Iontophoresis; Pulse wave velocity; Aortic augmentation index

Funding

  1. Coca-Cola Company

Ask authors/readers for more resources

Objective: To determine if (poly) phenols alter cardiovascular risk factors, we assessed the potential of a high (poly) phenol beverage drink, rich in hydroxycinnamates and flavonoids, to modify vascular function in middle aged, overweight or obese subjects without medical co-morbidity in a randomized placebo controlled pilot study. Methods: Randomly assigned active 250 ml beverages containing 361 mg of (poly) phenols and 120 mg of vitamin C or placebo (no polyphenol/vitamin C) were taken twice daily for 4 weeks. Both beverages contained 40 kcals/250 ml. The primary end-points were pulse wave velocity (PWV) and cutaneous microvascular responses to sodium nitroprusside (SNP) and acetyl choline (ACh) laser doppler iontophoresis. A range of established and novel plasma markers were also measured. Results: Twenty subjects received active beverage and 19 placebo; all completed the study. There was no difference in cutaneous vascular response to either SNP or ACh with mean group differences (logD area under perfusion curve) of 0.30 (-0.65, 1.26) and 0.35 (- 0.11, 0.81) respectively. Nor was there evidence of a change in log PWV with a mean group difference of 0.029 m/s (- 0.042, 0.10). No significant differences were seen in plasma leptin, apolipoproteins, cystatin C, insulin, adiponectin, CRP, ICAM-1, E-Selectin or tPA, but IL-6 increased in active versus placebo recipients (0.32 vs e 0.18 pg/ml; p = 0.010). Conculsion: There was no evidence for a short-term beneficial effect of (poly) phenol intervention on microcutaneous vascular response or pulse wave velocity, and no evidence for a benefit on established or novel risk factors in overweight or obese subjects. Our results do not support a short-term benefit of (poly) phenol supplementation on cardiometabolic risk. Registration: Clinical Trials.gov (NCT00795834). (C) 2016 Published by Elsevier Ireland Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available